(Q43864981)

English

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

3

object named as

Jaan Eha

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Matti Kivikko

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Saila Antila

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Lasse Lehtonen

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Pertti J Pentikäinen

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

43-51

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

The values and limitations of the QT interval in clinical practice

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Site dependent bioavailability and metabolism of levosimendan in dogs

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Right ventricular performance and contractile reserve in patients with severe heart failure. Assessment by pressure-area relations and association with outcome

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001005

21 January 2018

Identifiers

10.1177/0091270002042001005

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43864981&oldid=2143941575"